About us
About us
Founded in 2021 and led by a team of veteran biotherapeutics developers and protein engineers, Engimmune couples AI-guided innovation and laboratory insights to unlock the therapeutic potential of soluble TCR engagers. The company’s foundational technology is based on inventions by Dr. Rodrigo Vazquez-Lombardi and Prof. Sai Reddy. Engimmune closed its seed financing round in May 2022, which was co-led by Pureos Bioventures and Novo Holdings, and has since established a robust and differentiated pipeline of soluble TCR therapeutics.
Team
Sébastien Lalevée, PhD
Principal Scientist Immunology
Qinmei Yang, PhD
Research Scientist Immunology
Joseph Taft, PhD
Senior Scientist
Protein Engineering
Roy Ehling, PhD
Research Scientist Protein Engineering
Jakub Kucharczyk, PhD
Research Scientist
Protein Engineering
Sarah Wehrle, PhD
Research Scientist Protein Biochemistry/CMC
Valentin Junet, PhD
Data Scientist
Beichen Gao, PhD
Data Scientist
Tamara Lichtenstein, MSc
Research Associate
Protein Engineering
Juliette Forster, MSc
Research Associate ​
Protein Engineering
Chiara Lamanna, MSc
Research Associate
Protein Engineering
Raphael Ruch, MSc
Research Associate
Protein Engineering
Marie-Charlotte Diringer, MSc
Research Associate Immunology
Joshua Kämpf, MSc
Research Associate Immunology
Maria Franceskin, MSc
Research Associate Immunology
Marcela Vaz, PhD
Laboratory Manager
Martón Horváth, MSc
Research Associate Protein Biochemistry/CMC
Camille Wagner, MSc
Research Associate Protein Biochemistry/CMC
Board of Directors
